Core Viewpoint - Boston Scientific has completed the acquisition of SoniVie, entering the competitive renal denervation (RDN) market, which is expected to benefit millions of patients with hypertension [1][3]. Acquisition Details - Boston Scientific was previously a strategic investor in SoniVie, holding approximately 10% of its shares. The company paid about $360 million for the remaining 90% of shares, with potential regulatory milestone payments of up to $180 million, valuing the total transaction at approximately $600 million (around 4.3 billion RMB) [3]. - The acquisition is seen as a significant advancement in the treatment of hypertension through renal denervation, with positive results from ongoing clinical trials [3]. TIVUS System Overview - The TIVUS intravascular ultrasound system, developed by SoniVie, aims to treat various hypertension diseases through renal denervation [6]. - TIVUS can reduce renal nerve activity and serves as an alternative or adjunct therapy to antihypertensive medications, potentially offering a faster and more effective treatment method compared to radiofrequency energy [9][11]. - The system is designed for a single effective treatment, simplifying the procedure without causing vascular blockage, thus maintaining normal blood flow [13]. Research Progress - The REDUCED-1 pilot study, involving 40 patients, demonstrated the unique 'non-contact' RDN device, which does not require contact with the renal artery wall [14]. - The THRIVE study, approved by the FDA, aims to validate the efficacy and safety of the TIVUS system in treating hypertension patients [15]. RDN Market Overview - The global RDN market was valued at $1.5 billion in 2022 and is projected to reach $3.8 billion by 2030, with a compound annual growth rate (CAGR) of 12.5% from 2024 to 2030 [19]. - Key technologies in RDN include radiofrequency, ultrasound, and micro-infusion, with radiofrequency being the most widely used method [20]. Product Highlights - Recor Medical's Paradise RDN system, approved by the FDA, utilizes high-intensity focused ultrasound to ablate renal sympathetic nerves without direct contact with the vessel wall [21]. - Medtronic's Symplicity Spyral RDN system became the first to receive regulatory approval in the US, EU, and China for hypertension treatment [23]. - New products from domestic companies like Xinmai Medical and Meiliweiye are also entering the market, showcasing innovative solutions for renal denervation [27][31]. Conclusion - The global RDN market is experiencing rapid growth, supported by technological advancements and increased clinical validation. Major players like Boston Scientific and Medtronic hold significant positions, while domestic companies are emerging with innovative products, promising effective treatment options for hypertension patients [32].

报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2025年4月23日，波士顿科学 Boston Scientific (NYSE:BSX) 公布2025年第一季度业绩，第一季度总营收达到 46.63亿美元（合约340.1亿人民币） ， 销售额增长 20.9% ，净利润大幅增长 36.2% ，并且上调了其全年业绩指引。 在23日的早盘交易中，波士顿科学股价上涨 超过5% ，达到每股100.28美元，同期标准普尔500指数上涨 超过2% 。 # 财 报 详情 第一季度总体净销售额达到 46.63亿美元 ，按报告增长20.9%；GAAP每股收益为0.45美元， 调整后的每股收益达到0.75美元。 | | Three Months Ended | | | | | | --- | --- | --- | --- | --- | --- | | | March 31, | | | | Reported | | (in millions) | 2025 | | 2024 | | Basis | | Endoscopy | র্ব | 673 | दे | 642 | 4.7 % | | U ...